Claim Ledger
58% answered
Did management answer the analysts?
12 analyst questions audited, 3 evaded or deflected.
View Claim Ledger →Cipla Ltd — Q3 FY24
Cipla delivered a strong Q3 FY24 with revenue of INR 6,544 crore (+14% YoY) and EBITDA margin of 26.3%, driven by market-leading growth in India (+12%), an all-time high US revenue of $230 million (+18% YoY), and robust SAGA performance.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a strong Q3 FY24 with revenue of INR 6,544 crore (+14% YoY) and EBITDA margin of 26.3%, driven by market-leading growth in India (+12%), an all-time high US revenue of $230 million (+18% YoY), and robust SAGA performance. The India chronic portfolio outpaced the market, while US growth was fueled by seasonality and Lanreotide (20% market share). Management guided FY24 EBITDA margins at the higher end of 23-24% and expects Q4 seasonality weakness. Key pipeline updates include Symbicort filing, Advair filing by mid-FY25, and four peptide launches in FY25. Risks include US FDA observations at Indore (warning letter) and Goa facilities, potential pricing compression in US generics, and delays in Abraxane launch.
सिप्ला ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई 6,544 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। मुनाफा कमाने की क्षमता (EBITDA मार्जिन) 26.3% रही। भारत में बिक्री 12% बढ़ी और अमेरिका में 230 मिलियन डॉलर की रिकॉर्ड बिक्री हुई। कंपनी ने कहा कि पूरे साल मुनाफा 23-24% के ऊपरी स्तर पर रहेगा। आगे नई दवाएं लॉन्च होंगी, लेकिन अमेरिका में कीमतों में कमी और फैक्ट्री जांच से जुड़े जोखिम हैं।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Risks
4 risks
Risk Intelligence
US FDA warning letter at Indore facility
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Revenue
$230M
+18% YoY
All-time high quarterly US revenue, 15th consecutive quarter of YoY growth.
India Business Growth
12%
+12% YoY
India business grew 12% YoY, with chronic portfolio growing 13% vs IPM 11%.
Lanreotide Market Share
20%
Flat QoQ
Lanreotide 505(b)(2) maintained 20% market share; incremental growth expected.
Chronic Portfolio Share
60.3%
+115bps YoY
Share of chronic therapies in India branded prescription portfolio improved to 60.3%.
What Changed vs Last Quarter
NEW
Advair filing by mid-FY25
Advair generic expected to be filed by mid-FY25 from an alternate site, with approval likely by end of next fiscal.
NEW
Four peptide launches in FY25
Four peptide launches planned in FY25, with one asset awaiting approval expected in Q1 FY25.
UPDATED
FY24 EBITDA margin at higher end of 23-24%
Full-year EBITDA margin trending at the higher end of the previously guided range of 23-24%.
UPDATED
Symbicort filing completed
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
DROPPED
Peptide product launch in Q4 FY24
One peptide product launch planned in Q4 FY24, with 3-4 more in FY25.
DROPPED
US revenue sustainable range of $220-225M next quarter
Management guided US revenue of $220-225M as sustainable for the next quarter.
NEW RISK
US FDA warning letter at Indore facility
Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.
NEW RISK
Goa facility re-inspection uncertainty
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
NEW RISK
US generic pricing compression
Pricing environment in US generics is in a downcycle; compression expected to move from 4-6% to 6-8% within a year.
NEW RISK
Abraxane launch delay
Abraxane launch via third-party transfer is taking longer; fastest route is from Goa facility, which is subject to FDA inspection.
RISK GONE
Indore facility OAI classification
Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.
RISK GONE
Albuterol market share volatility
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
RISK GONE
Revlimid volume uncertainty post-12-month period
Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
Fast read
Guidance and risk preview
Full-year EBITDA margin trending at the higher end of the previously guided range of 23-24%.
Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.
View Risks →